Neutrophil Elastase Increases Vascular Permeability and Leukocyte Transmigration in Cultured Endothelial Cells and Obese Mice.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
25 07 2022
Historique:
received: 25 04 2022
revised: 27 06 2022
accepted: 21 07 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 29 7 2022
Statut: epublish

Résumé

Neutrophil elastase (NE) plays a pivotal role in inflammation. However, the mechanism underlying NE-mediated inflammation in obesity remains unclear. Here, we report that NE activates protease-activated receptor-2 (PAR2), stimulates actin filament (F-actin) formation, decreases intercellular junction molecule VE-cadherin expression, and increases the permeability of human arterial endothelial cells (hECs). NE also prompts degradation of VE-cadherin and its binding proteins p120- and β-catenins via MG132-sensitive proteasomes. NE stimulates phosphorylation of myosin light-chain (MLC) and its regulator myosin phosphatase target subunit-1 (MYPT1), a target of Rho kinase (ROCK). Inhibitors of PAR2 and ROCK prohibit NE-induced F-actin formation, MLC phosphorylation, and VE-cadherin reduction in hECs, and impede monocyte transmigration through hEC monolayer pretreated with either neutrophils or NE. Further, administration of an NE inhibitor GW311616A significantly attenuates vascular leakage, leukocyte infiltration, and the expression of proinflammatory cytokines in the white adipose tissue from high-fat diet (HFD)-induced obese mice. Likewise, NE-deficient mice are resistant to HFD-induced vascular leakage in the heart. Together, NE regulates actomyosin cytoskeleton activity and VE-cadherin expression by activating PAR2 signaling in the endothelial cells, leading to increased vascular permeability and leukocyte extravasation. Hence, inhibition of NE is a potential approach to mitigate vascular injury and leukocyte infiltration in obesity-related systemic inflammation.

Identifiants

pubmed: 35892585
pii: cells11152288
doi: 10.3390/cells11152288
pmc: PMC9332277
pii:
doi:

Substances chimiques

Actins 0
Leukocyte Elastase EC 3.4.21.37

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK126949
Pays : United States
Organisme : NIDDK NIH HHS
ID : R56 DK121142
Pays : United States

Références

Circulation. 2011 Jul 5;124(1):48-57
pubmed: 21670231
Front Physiol. 2018 Feb 20;9:113
pubmed: 29515456
Front Immunol. 2019 May 09;10:1037
pubmed: 31143182
Nat Med. 2012 Sep;18(9):1407-12
pubmed: 22863787
Annu Rev Cell Dev Biol. 2020 Oct 6;36:191-218
pubmed: 32663035
PLoS One. 2013 Jun 18;8(6):e66743
pubmed: 23825105
J Clin Invest. 2003 Dec;112(12):1796-808
pubmed: 14679176
Nat Rev Immunol. 2006 Mar;6(3):173-82
pubmed: 16498448
Circ Res. 2000 Aug 18;87(4):335-40
pubmed: 10948069
Int J Mol Sci. 2019 Sep 07;20(18):
pubmed: 31500313
Mol Cell Biol. 2018 Mar 29;38(8):
pubmed: 29378832
Mol Biol Cell. 2017 Jan 1;28(1):30-40
pubmed: 27798235
Nat Med. 2005 Feb;11(2):183-90
pubmed: 15685173
Bioorg Med Chem Lett. 2001 Apr 9;11(7):895-8
pubmed: 11294386
Cell Commun Signal. 2013 May 28;11(1):37
pubmed: 23714586
Mol Pharmacol. 2005 Jan;67(1):78-87
pubmed: 15475570
Cells. 2020 Jan 17;9(1):
pubmed: 31963447
J Immunol. 2007 Sep 15;179(6):3988-94
pubmed: 17785837
Front Immunol. 2018 Apr 25;9:732
pubmed: 29922273
Biochem Soc Trans. 2020 Dec 18;48(6):2525-2537
pubmed: 33242065
J Biol Chem. 2009 Dec 4;284(49):34444-57
pubmed: 19815543
Nat Rev Cardiol. 2020 Jun;17(6):327-340
pubmed: 31996800
Front Endocrinol (Lausanne). 2014 May 13;5:67
pubmed: 24860547
Methods Mol Biol. 2014;1124:19-37
pubmed: 24504944
Am J Physiol Lung Cell Mol Physiol. 2004 Jun;286(6):L1143-53
pubmed: 14672921
Am J Physiol Cell Physiol. 2004 May;286(5):C987-97
pubmed: 15075197
J Lipid Res. 2008 Sep;49(9):1894-903
pubmed: 18503031
J Cell Biol. 2010 Nov 1;191(3):677-91
pubmed: 20974816
J Biol Chem. 2013 Apr 19;288(16):11203-15
pubmed: 23476015
Nat Rev Immunol. 2013 Mar;13(3):159-75
pubmed: 23435331
J Cell Biol. 2000 Mar 20;148(6):1267-81
pubmed: 10725339
Nat Rev Endocrinol. 2012 Dec;8(12):709-16
pubmed: 22847239
Cell Rep. 2014 Aug 7;8(3):883-96
pubmed: 25066128
J Pharmacol Exp Ther. 2018 Feb;364(2):246-257
pubmed: 29263243
Trends Immunol. 2009 Nov;30(11):547-56
pubmed: 19783480
J Biol Chem. 2003 May 23;278(21):19199-208
pubmed: 12626512
Microcirculation. 2011 Jan;18(1):46-55
pubmed: 21166925
Korean J Intern Med. 2005 Dec;20(4):275-83
pubmed: 16491824
J Clin Invest. 2003 Dec;112(12):1821-30
pubmed: 14679177
Cell Tissue Res. 2014 Mar;355(3):515-22
pubmed: 24643676
Cell Adh Migr. 2014;8(2):158-64
pubmed: 25422846
Arch Pharm Res. 2017 Dec;40(12):1443-1454
pubmed: 29098568
J Biol Chem. 1999 Jun 25;274(26):18524-35
pubmed: 10373461
Curr Opin Hematol. 2007 Jan;14(1):3-8
pubmed: 17133093
Nat Rev Immunol. 2018 Feb;18(2):134-147
pubmed: 28990587
Atherosclerosis. 2016 May;248:97-109
pubmed: 26994427
Circulation. 2019 Aug 6;140(6):487-499
pubmed: 31170826
Front Immunol. 2017 Feb 06;8:81
pubmed: 28220120
Pulm Circ. 2014 Dec;4(4):535-51
pubmed: 25610592
Small GTPases. 2019 Nov;10(6):466-484
pubmed: 28949796
Front Cell Dev Biol. 2021 Sep 09;9:718586
pubmed: 34568331
Science. 1993 Jan 1;259(5091):87-91
pubmed: 7678183
Cent Eur J Immunol. 2020;45(4):461-468
pubmed: 33658893
Front Physiol. 2020 May 21;11:519
pubmed: 32670077
J Biol Chem. 2013 May 31;288(22):15830-42
pubmed: 23589307
Cell Adh Migr. 2014;8(2):125-35
pubmed: 24621569
J Biol Chem. 2017 Mar 24;292(12):4770-4776
pubmed: 28202548
J Biol Chem. 2011 Jul 15;286(28):24638-48
pubmed: 21576245
Circ Res. 2003 Feb 21;92(3):272-8
pubmed: 12595338
J Biol Chem. 2015 May 29;290(22):13875-87
pubmed: 25878251
Nat Rev Immunol. 2011 Jul 25;11(8):519-31
pubmed: 21785456
J Cell Biochem. 2017 Dec;118(12):4587-4593
pubmed: 28485540
Trends Mol Med. 2021 Apr;27(4):314-331
pubmed: 33309601
Front Immunol. 2020 Sep 18;11:2091
pubmed: 33072072
Cytoskeleton (Hoboken). 2010 Sep;67(9):545-54
pubmed: 20803696
Front Pharmacol. 2020 Jan 21;10:1568
pubmed: 32038245
Cell Metab. 2013 Apr 2;17(4):534-48
pubmed: 23562077
J Clin Invest. 2011 Jun;121(6):2111-7
pubmed: 21633179
Int J Mol Sci. 2021 Jan 08;22(2):
pubmed: 33429925

Auteurs

Chinchu Jagadan Ushakumari (CJ)

Department of Pharmacology & Experimental Therapeutics, School of Medicine, Boston University, Boston, MA 02118, USA.
Whitaker Cardiovascular Institute, School of Medicine, Boston University, Boston, MA 02118, USA.

Qiong L Zhou (QL)

Department of Pharmacology & Experimental Therapeutics, School of Medicine, Boston University, Boston, MA 02118, USA.
Whitaker Cardiovascular Institute, School of Medicine, Boston University, Boston, MA 02118, USA.

Yu-Hua Wang (YH)

Department of Pharmacology & Experimental Therapeutics, School of Medicine, Boston University, Boston, MA 02118, USA.
Whitaker Cardiovascular Institute, School of Medicine, Boston University, Boston, MA 02118, USA.

Sijia Na (S)

Department of Pharmacology & Experimental Therapeutics, School of Medicine, Boston University, Boston, MA 02118, USA.
Whitaker Cardiovascular Institute, School of Medicine, Boston University, Boston, MA 02118, USA.

Michael C Rigor (MC)

Whitaker Cardiovascular Institute, School of Medicine, Boston University, Boston, MA 02118, USA.

Cindy Y Zhou (CY)

Whitaker Cardiovascular Institute, School of Medicine, Boston University, Boston, MA 02118, USA.

Max K Kroll (MK)

Whitaker Cardiovascular Institute, School of Medicine, Boston University, Boston, MA 02118, USA.

Benjamin D Lin (BD)

Whitaker Cardiovascular Institute, School of Medicine, Boston University, Boston, MA 02118, USA.

Zhen Y Jiang (ZY)

Department of Pharmacology & Experimental Therapeutics, School of Medicine, Boston University, Boston, MA 02118, USA.
Whitaker Cardiovascular Institute, School of Medicine, Boston University, Boston, MA 02118, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH